These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 22717544

  • 21. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy.
    Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahlöf B, Edelman JM, Devereux RB.
    Eur Heart J; 2010 Sep; 31(18):2271-9. PubMed ID: 20601389
    [Abstract] [Full Text] [Related]

  • 22. Effect of changing heart rate during treatment of hypertension on incidence of heart failure.
    Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahlöf B, Devereux RB.
    Am J Cardiol; 2012 Mar 01; 109(5):699-704. PubMed ID: 22154318
    [Abstract] [Full Text] [Related]

  • 23. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB.
    J Am Coll Cardiol; 2005 Mar 01; 45(5):712-9. PubMed ID: 15734615
    [Abstract] [Full Text] [Related]

  • 24. Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study.
    Søraas CL, Wachtell K, Okin PM, Dahlöf B, Devereux RB, Tønnessen T, Kjeldsen SE, Olsen MH.
    Blood Press; 2010 Jun 01; 19(3):145-51. PubMed ID: 20429689
    [Abstract] [Full Text] [Related]

  • 25. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
    Ibsen H, Pedersen OL, Dahlöf B, Kjeldsen SE, Lindholm LH.
    Ugeskr Laeger; 2003 Jan 27; 165(5):456-9. PubMed ID: 12599843
    [Abstract] [Full Text] [Related]

  • 26. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
    Wachtell K, Gerdts E, Aurigemma GP, Boman K, Dahlöf B, Nieminen MS, Olsen MH, Okin PM, Palmieri V, Rokkedal JE, Devereux RB.
    Blood Press; 2010 Jun 27; 19(3):169-75. PubMed ID: 20438307
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB, de Faire U, Fyhrquist F, Harris KE, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Hille DA, Dahlöf B.
    Curr Med Res Opin; 2007 Feb 27; 23(2):259-70. PubMed ID: 17288679
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study.
    Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Lindholm LH, Dahlöf B, LIFE Study Investigators.
    Hypertension; 2007 Nov 27; 50(5):984-90. PubMed ID: 17893425
    [Abstract] [Full Text] [Related]

  • 32. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB.
    J Am Coll Cardiol; 2005 Mar 01; 45(5):705-11. PubMed ID: 15734614
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure.
    Okin PM, Wachtell K, Gerdts E, Dahlöf B, Devereux RB.
    J Hypertens; 2014 Dec 01; 32(12):2472-8; discussion 2478. PubMed ID: 25340854
    [Abstract] [Full Text] [Related]

  • 35. Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.
    Kjeldsen SE, Devereux RB, Hille DA, Lyle PA, Dahlöf B, Julius S, Edelman JM, Snapinn SM, de Faire U, Fyhrquist F, Ibsen H, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H.
    Blood Press; 2009 Dec 01; 18(6):348-61. PubMed ID: 20001655
    [Abstract] [Full Text] [Related]

  • 36. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
    Carr AA, Kowey PR, Devereux RB, Brenner BM, Dahlöf B, Ibsen H, Lindholm LH, Lyle PA, Snapinn SM, Zhang Z, Edelman JM, Shahinfar S.
    Am J Cardiol; 2005 Dec 01; 96(11):1530-6. PubMed ID: 16310435
    [Abstract] [Full Text] [Related]

  • 37. Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Ruwald AC, Westergaard B, Sehestedt T, Kjeldsen SE, Lindholm LH, Wachtell K, Devereux RB, Ibsen H, Nieminen MS, Dahlöf B, Olsen MH.
    J Hypertens; 2012 Jun 01; 30(6):1252-9. PubMed ID: 22499288
    [Abstract] [Full Text] [Related]

  • 38. Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study.
    Olsen MH, Wachtell K, Beevers G, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Narayan P, Nieminen MS, Omvik P, Oparil S, Wedel H.
    Am Heart J; 2009 Jan 01; 157(1):177-84. PubMed ID: 19081416
    [Abstract] [Full Text] [Related]

  • 39. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
    Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Aurup P, Edelman J, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H, LIFE (Losartan Intervention for Endpoint Reduction) Study Group.
    JAMA; 2002 Sep 25; 288(12):1491-8. PubMed ID: 12243636
    [Abstract] [Full Text] [Related]

  • 40. Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension.
    Okin PM, Hille DA, Kjeldsen SE, Devereux RB.
    J Am Heart Assoc; 2017 Nov 18; 6(11):. PubMed ID: 29151037
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.